Edison Investment Research - Pharmaceuticals & healthcare - ASIT biotech: ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive of ASIT's short-course adjuvant-free approach to allergy vaccination. The study demonstrated both immunological and symptomatic responses that persisted until the end of the pollen season.
ISIN: BE0974289218Den vollständigen Artikel lesen ...
ISIN: BE0974289218Den vollständigen Artikel lesen ...